A dark side to NS1 antibodies?

J Exp Med. 2021 Sep 6;218(9):e20211348. doi: 10.1084/jem.20211348. Epub 2021 Jul 28.

Abstract

The NS1 protein of flaviviruses is taking center stage. Recent work has made it an attractive target for development of vaccines and immunotherapeutics. Cavazzoni and colleagues (2021. J. Exp. Med.https://doi.org/10.1084/jem.20210580) now reveal a dark side to NS1, linking it to the development of self-reactive antibodies.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment